China
Africa
Explore chapters and articles related to this topic
Nanoparticles from Marine Biomaterials for Cancer Treatment
Published in Se-Kwon Kim, Marine Biochemistry, 2023
Another distinguishing feature of HA is its ability to bind with particular cancer cell receptors, such as CD44, and activate macrophages. It plays an essential role in cancer diagnostic and therapy research because of this characteristic. NPs can also be formulated into NPs for cancer treatment. As macromolecular prodrugs, HA-drug conjugates have been created for cancer treatment. For usage as a targeting moiety, HA has also been conjugated onto different drug-loaded NPs (Lapčík et al. 1998). When compared to free anticancer drugs, these HA conjugates containing anticancer agents such as paclitaxel, doxorubicin butyric acid, mitomycin C, and siRNA had better tumor targeting and therapeutic effectiveness (Choi et al. 2010). Studies with HA are more limited compared to other marine components. Park et al. created bioinspired monodisperse magnetite nanocrystals (HA-DN/MNC) for targeted cancer imaging with HA. They immobilized HA onto iron oxide nanocrystals to target cancer cells with CD44 overexpression. Via CD44-HA receptor–ligand interaction and ensure the detection of cancer cells through CD44-HA receptor–ligand interactions (Lee et al. 2008).
Targeted Therapy for Cancer Stem Cells
Published in Surinder K. Batra, Moorthy P. Ponnusamy, Gene Regulation and Therapeutics for Cancer, 2021
Rama Krishna Nimmakayala, Saswati Karmakar, Garima Kaushik, Sanchita Rauth, Srikanth Barkeer, Saravanakumar Marimuthu, Moorthy P. Ponnusamy
CD44 like CD133 is a transmembrane glycoprotein that facilitates cell-cell and cell to ECM interactions and is found to be overexpressed in several cancers. Study on patient-derived AML blasts has revealed that treatment with anti-human CD44 monoclonal antibody to stimulate myeloid differentiation alters stem cell fate, and impedes homing to the microenvironment niche [81]. Doxorubicin and cyclophosphamide, in combination with anti-human CD44 antibody, have shown synergistic anti-cancerous activity in breast cancer and prevent relapse of aggressive breast cancer [82]. Another study by Tang et al. [83] used a mouse IgG1 anti-human CD44 receptor antibody on MiaPaCa-2 cells and was shown to inhibit CSCs tumorsphere formation, also decreasing tumor growth, metastasis and recurrence in pancreatic cancer xenografted nude mice.
Filler Materials: Indications, Contraindications, and Special Considerations in Oncology Patients
Published in Paloma Tejero, Hernán Pinto, Aesthetic Treatments for the Oncology Patient, 2020
This is a material for which we also have some studies linked to the cancer patient, exploring its possible role in the prevention of adverse effects after radiotherapy [21–23]. Some authors consider it a safe alternative to HA [24], although it does not have the same number of studies, experience, and versatility. However, in the cancer patient, it could have as an additional advantage that it does not join the CD44 receptor or is present in the tumor microenvironment.
Hyaluronic acid-based nanoparticles to deliver drugs to the ocular posterior segment
Published in Drug Delivery, 2023
Multiple HA receptors have been identified with multiple biological functions through hyaladherins, including cluster-determined 44 (CD44), receptor for hyaluronate-mediated motility, HA receptor for endocytosis, and lymphatic vessel endothelial hyaluronan receptor-1 (X. Zhang et al., 2021). Among them, CD44 has been investigated and applied most thus far. CD44 is a type I membrane glycoprotein with a transmembrane domain, a heavily glycosylated membrane-proximal region, a short cytoplasmic domain, and an N-terminal HA binding domain (Heldin et al., 2020). It can interact with other ligands, such as fibronectin, collagen, and matrix metalloproteinases. CD44 is not only critical for cell migration, inflammatory processes, lymphocyte localization, and cell proliferation but also helps with HA removal and healing after wounding or other types of damage (Garantziotis & Savani, 2019). CD44 can bind and internalize HA via van der Waals forces or H-bonds to inhibit inflammation, neovascularization, and cancer metastasis (Li, Sun et al., 2021). HA is a promising ligand for cancer-targeting nanoparticles due to the high expression of CD44 in cancers (Chen, Li et al., 2021; Gu et al., 2021; Li, Sun et al., 2021; D. Liu et al., 2021; Wang, Zhang et al., 2021).
The most promising microneedle device: present and future of hyaluronic acid microneedle patch
Published in Drug Delivery, 2022
Huizhi Kang, Zhuo Zuo, Ru Lin, Muzi Yao, Yang Han, Jing Han
CD44 contains a HA binding domain or chondroitin domain, a membrane-proximal structural domain, and a cytoplasmic tail. It is an abundant and functionally important receptor expressed in a variety of cell types such as leukocytes, fibroblasts, epithelial cells, keratinocytes, and some endothelial cells (Misra et al., 2011). A large number of HA receptors, CD44, exist on the surface of certain superficial epidermal solid tumors. HA is used as a targeting carrier for anti-tumor drugs, and using HA MNP can wrap drug molecules in the three-dimensional structure of the HA MNP matrix. With the degradation of the needle body, the drugs which adhered to HA release, and tumor cell surface receptors targeted binding to increase the absorption and retention time of the drug in the tumor. Thus, the efficacy of the drug is improved and toxic side effects are reduced.
Oxymatrine protects against l -arginine-induced acute pancreatitis and intestine injury involving Th1/Th17 cytokines and MAPK/NF-κB signalling
Published in Pharmaceutical Biology, 2019
Zhiqiang Zhang, Qingfeng Liu, Hui Zang, Qingliang Shao, Tian Sun
Finally, OMT inhibited Arg-induced CD44 and CD54 (ICAM-1) expression in vivo. CD44 and CD54 play significant roles in inflammatory response in vivo. CD44 promoted inflammation and extracellular matrix production during arteriovenous fistula maturation (Kang et al. 2013). Specific inhibition of ICAM-1 effectively reduced bladder inflammation in rat with severe non-bacterial cystitis (Zhang et al. 2016b). An anti-human ICAM-1 antibody inhibited rhinovirus-induced exacerbations of lung inflammation (Traub et al. 2013). Meanwhile, intestinal reperfusion resulted in an increase of systemic ICAM-1 expression with marked organ variability in rats (Olanders et al. 2002). Therefore, OMT also inhibited Arg-induced intestinal injury via inhibiting CD44- and CD55-mediated inflammation.